Klaviyo, Inc.

KVYO

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 15,555Value: $506K

**Signal Note: Eventide Initiates KVYO Position** Eventide's $506K entry into Klaviyo appears inconsistent with typical biotech-focused mandates, suggesting either portfolio diversification or conviction in KVYO's SaaS/martech fundamentals rather than pipeline-driven catalysts. This positioning shift warrants monitoring for strategic intent, though it lacks the drug development or clinical catalysts typical of values-based biotech allocations.

More KVYO Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: